Bavarian Nordic bites back in chikungunya vaccine race, hitting phase 3 goal to stay on Valneva's heels

Bavarian Nordic’s phase 3 chikungunya virus vaccine clinical trial has hit its primary endpoint, keeping the Danish drugmaker in the slipstream of Valneva’s near-approval candidate in the race to market.